The Quest to Develop the First Alzheimer’s Disease Treatment

The reasons Pfizer recently decided to stop pursuing neurological disease research and what to look forward to in the near future regarding Alzheimer's disease treatmentsRelated Stocks: NVS, GILD, CELG, ONCE, PFE, AXON, MRK, LLY, BIIB, PRAN, JNJ,.....»»

Category: worldSource: nytFeb 13th, 2018

Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814 Eli Lilly and Company LLY and AstraZeneca plc AZN expanded their existing collaboratio.....»»

Category: topSource: zacksDec 12th, 2016

Eli Lilly and AstraZeneca to co-develop Alzheimer"s Disease treatment

Eli Lilly & Co. and AstraZeneca Plc said Friday they have entered an agreement to jointly develop an Alzheimer's Disease treatment. The companies will work together on MEDI1814, an antibody selective for amyloid-beta 42, which is currently in Phase 1 tr.....»»

Category: topSource: marketwatchDec 9th, 2016

Eli Lilly to pay AstraZeneca $30 million as part of a collaboration on an Alzheimer"s treatment

Eli Lilly & Co. and AstraZeneca PLC announced Friday an agreement to develop a potential treatment for Alzheimer's disease that is currently in Phase 1 trials. As part of the agreement, Lilly will make a $30 million upfront payment to AstraZeneca. Lilly.....»»

Category: topSource: marketwatchDec 9th, 2016

Eli Lilly Alzheimer"s Drug Fails Trial; Shares Plunge

An experimental Eli Lilly drug failed to significantly help Alzheimer’s disease patients in a closely watched clinical trial, dealing another blow to the pharmaceutical industry’s long quest to find a better treatment for the condition......»»

Category: smallbizSource: wsjNov 23rd, 2016

Merck (MRK) Halts Another Late Stage Study on Alzheimer"s

Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an .....»»

Category: smallbizSource: nytFeb 14th, 2018

Alzheimer"s Study Discovers Toxic Protein Behind Disease That Could Radically Change Treatment Research

We may have been mistaken when it comes to what causes Alzheimer's disease......»»

Category: topSource: newsweekJan 24th, 2018

Alzheimer"s takes Another Hit as Pfizer Ends Research in this Area

With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, her.....»»

Category: worldSource: nytJan 8th, 2018

It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)

AP/Alastair GrantThe search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years.  The latest failure came in September, when Axovan.....»»

Category: topSource: businessinsiderOct 8th, 2017

Alzheimer"s Drug: Promising Treatment From Axovant Fails Clinical Trial

Intepirdine did not demonstrate improvements in cognition and functioning in patients with mild-to-moderate Alzheimer's disease......»»

Category: topSource: newsweekSep 26th, 2017

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease......»»

Category: blogSource: 247wallstSep 26th, 2017

The Wall Street Journal: Axovant shares plummet 74% on failure of Alzheimer’s disease trial

Many companies are working to develop an Alzheimer’s disease treatment, but it has been a difficult path......»»

Category: topSource: marketwatchSep 26th, 2017

Analyst: Neurotrope"s Bryostatin-1 Trial Data Justifies Additional Studies

Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday.....»»

Category: blogSource: benzingaMay 1st, 2017

Novartis Tests New Alzheimer"s Drugs on People Who Don"t Have the Disease

Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment......»»

Category: smallbizSource: wsjApr 22nd, 2017

U.S. FDA Allows 23andMe to Sell Genetic Tests for 10 Diseases

The U.S. Food and Drug Administration on Thursday agreed to allow genetic testing company 23andMe to market tests directly to consumers to assess their predisposition to develop 10 diseases, including Parkinson's, Alzheimer's and Celiac disease......»»

Category: topSource: foxnewsApr 6th, 2017

After Merck Stops Study, What Remains Of The Alzheimer"s Drug Pipeline?

Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people with mild to moderate Alzheimer's disease (AD) afte read more.....»»

Category: blogSource: benzingaFeb 16th, 2017

Merck halts trial of once "promising" Alzheimer"s drug

US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work......»»

Category: topSource: moneycentralFeb 15th, 2017

Another Potential Alzheimer"s Disease Treatment Bites the Dust: What"s Next?

Merck's verubecestat becomes the latest casualty in treating Alzheimer's disease. Is there any hope in sight for this dreaded disease?.....»»

Category: topSource: foxnewsFeb 15th, 2017

This Could Very Well Be the Greatest Drug Advancement in a Decade

Is new hope on the horizon for Alzheimer's disease patients? This drug's initial trial results suggest a new treatment could be coming......»»

Category: topSource: foxnewsJan 9th, 2017

Anavex 2-73: The Right Path To The Treatment Of Alzheimer"s Disease?

Anavex 2-73: The Right Path To The Treatment Of Alzheimer"s Disease?.....»»

Category: topSource: seekingalphaDec 12th, 2016

AC Immune Out Positive On Crenezumab; What Does It Mean?

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published a.....»»

Category: blogSource: benzingaDec 12th, 2016